Management of Penile Bleeding in Patients on Anticoagulation and Antiplatelet Therapy

Immediate Management

The American College of Cardiology recommends holding both Eliquis (apixaban) and Plavix (clopidogrel) immediately in a patient with active penile bleeding, as this represents ongoing pathological bleeding requiring temporary discontinuation of anticoagulation and antiplatelet therapy 1, 2
Determine if the bleeding is major by evaluating hemodynamic stability, need for transfusion, hemoglobin drop, and baseline anemia, with the European Heart Journal citing the importance of assessing hemodynamic stability 3, 1

Discontinue Eliquis (apixaban) immediately for any major bleeding, with consideration of andexanet alfa if bleeding is life-threatening or uncontrolled, as recommended by the Journal of the American College of Cardiology 4, 5, 1
The American College of Cardiology advises that concomitant antiplatelet agents, such as Plavix (clopidogrel), should be discontinued safely in bleeding situations, with understanding that clopidogrel causes irreversible platelet inhibition lasting 7-10 days 4, 1, 2

Rapidly assess thrombotic risk before holding medications, with high-risk scenarios including recent acute coronary syndrome or coronary stent placement, as outlined by the European Heart Journal and the Journal of the American College of Cardiology 7, 6, 3, 8
The European Society of Cardiology warns that interrupting both antiplatelet drugs in ongoing major bleeding may magnify platelet reactivity leading to stent thrombosis, emphasizing the need for urgent cardiology consultation in high-risk patients 3, 8

Arrange urgent urologic evaluation to identify and treat the bleeding source, with determination of the need for invasive procedure influencing the duration of medication hold, as recommended by the Journal of the American College of Cardiology 1, 2

Resume medications when hemostasis has been achieved, bleeding source identified and treated, patient is clinically stable, and there is no ongoing transfusion requirement, with timing considerations including resuming apixaban 24-48 hours after hemostasis and clopidogrel within 2-3 days if high thrombotic risk, as outlined by the Journal of the American College of Cardiology and the European Heart Journal 4, 3, 1, 2
If the patient had recent ACS or stent (within 6 months), strongly consider resuming at least one antiplatelet agent (aspirin) within 24 hours after achieving hemostasis, with cardiology guidance, as recommended by the European Heart Journal and the Journal of the American College of Cardiology 7, 3, 8